Study to assess the effect of JMKX001899 on QTc interval in healthy volunteers
A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of JMKX001899 Administered as a Tablet Formulation Under Fed Conditions in Healthy Subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
27
Participants will receive JMKX001899 500mg tablet, orally once on Day 1
Participants will receive JMKX001899 750mg tablet, orally once on Day 1
Participants will receive JMKX001899 1000mg tablet, orally once on Day 1
To evaluate the effect of a single dose of JMKX001899 on the change in time-matched QTc intervals compared with placebo
QTc interval was measured by electrocardiograms to evaluate the potential effect of JMKX001899 plasma concentrations on the QTc interval using linear mixed-effect exposure-response modeling, including the predicted ddQTc at Cmax values corresponding to exposure levels
Time frame: 48 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Participants will receive JMKX001899 matching placebo, tablet, orally once on Day 1